Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
It has been demonstrated that itakalim hydrochloride (Ipt) reverses the remodeling of the pulmonary resistance vascular system, inhibits the growth of smooth muscle cells in the pulmonary artery (PASMC) and airway (ASMC), and shields PAEC from pathogenic stimuli [1]. Through the activation of KATP channels, iptakalim inhibits the rise in [Ca2+]cyt and pulmonary artery SMC proliferation that is produced by endothelin 1. Iptakalim (10 μM, 10 min) pretreatment of pulmonary artery SMC effectively inhibited the transient rise in [Ca2+] cells produced by endothelin-1 [2]. At doses of 0.1, 1 and 10 AM, iptakalim decreased [3H]thymidine incorporation by 19.75±4.60% (n = 10), 41.20±9.49% (n = 10), and 54.74±10.11% (n = 10). ), in contrast to cells that were only treated with endothelin-1 [2].
|
---|---|
ln Vivo |
Pretreatment with Iptakalim (60 mg/kg) considerably reduced activity (LSD comparison). Iptakalim (10-60 mg/kg) attenuates chamber activity during these nicotine tests. Iptakalim also attenuates nicotine-induced conditioned responses [3].
|
Animal Protocol |
Animal/Disease Models: 30 male SD (SD (Sprague-Dawley)) rats, weighing 275-299 grams [3].
Doses: 0, 10, 30 or 60 mg/kg. Route of Administration: IP, 4 minutes 10 minutes before test session starts Experimental Results: diminished chamber activity. Dipper entries after pretreatment with 30 and 60 mg/kg Iptakalim were Dramatically lower than those pretreated with 0 (saline) or 10 mg/kg Iptakalim (Tukey HSD test). |
References |
|
Molecular Formula |
C9H21N.HCL
|
---|---|
Molecular Weight |
179.731
|
CAS # |
642407-63-4
|
Related CAS # |
642407-44-1(free base);642407-63-4 (HCl);
|
PubChem CID |
11446679
|
Appearance |
Yellow to orange solid powder
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
1
|
Rotatable Bond Count |
3
|
Heavy Atom Count |
11
|
Complexity |
92.9
|
Defined Atom Stereocenter Count |
0
|
SMILES |
CC(C)C(C)(C)NC(C)C.[H]Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~25 mg/mL (~139.10 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (556.39 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.5639 mL | 27.8195 mL | 55.6390 mL | |
5 mM | 1.1128 mL | 5.5639 mL | 11.1278 mL | |
10 mM | 0.5564 mL | 2.7820 mL | 5.5639 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.